Typbar Typhoid Conjugate Vaccine
Bharat Biotech’s Typbar TCV, the world’s first clinically proven typhoid conjugate vaccine, has received pre-qualification from the World Health Organisation (WHO). It is the fourth generation vaccine against typhoid, proven to provide long-term protection to adults and infants – six months and older.
Originally written on
April 7, 2018
and last modified on
December 1, 2019.
| Related | |
|---|---|
